Programmable Virtual Human

Test drugs in a virtual human before the first patient

An AI-powered platform that simulates how molecules interact with the human body across multiple scales, from cellular mechanisms to integrated organ systems.

Explore the Platform

The Challenge

Drug discovery is broken. We lose promising therapeutics not to bad science, but to blind spots.

>90%

of drug candidates fail in clinical trials, primarily because early predictions rarely translate to clinical success in complex biological systems.

$2.6B

average cost to bring a single drug to market, with the majority of investment lost to late-stage failures due to unforeseen toxicity or limited efficacy.

10-15yr

typical development timeline from discovery to approval, while patients wait for therapies that could transform their outcomes.

The Platform

A biological compiler for drug discovery

PVH creates comprehensive simulations of human biology by integrating AI, high-throughput experimental biology, single-cell analytics, and real-world evidence. Rather than iterating through countless design cycles, it systematically identifies optimal therapeutic interventions.

Predict Response

Forecast therapeutic responses with unprecedented accuracy before entering clinical testing, reducing uncertainty and accelerating development.

Identify Toxicity

Detect potential adverse effects and toxicity profiles during early development stages, preventing costly late-stage failures.

Optimize Molecules

Engineer molecules with optimized therapeutic indices, maximizing efficacy while minimizing harm through systematic virtual iteration.

Bridge the Gap

Close the critical gap between preclinical research and clinical outcomes by capturing the intricate network of biological interactions.

The Team

Dark Matter Therapeutics Founding Team

Steven Zimmer

CEO, Co-Founder

Serial Entrepreneur: Protein Sciences, Co-Founder; EpiCombi.AI, Founder and CEO; Advisor to various start-ups

Prof. Lei Xie, Ph.D.

CSO, Founder

Professor, City University of New York (CUNY) and Adjunct Professor, Weill Cornell Medicine, Cornell University. Newly appointed and moving to Northeastern University. Former researcher at Roche.

Prof. Philip E. Bourne, Ph.D.

Advisor, Co-Founder

Founding Dean, School of Data Science at Protein Data Bank; President of ISCB; Founding chief editor of PLOS Computational Biology

You Wu, PhD

Co-Founder, Senior Principal Scientist

Earned a PhD in Computer Science from City University of New York. Expert in application of AI/ML to drug discovery and early development.